The effectiveness of thiamine on cognitive symptoms after electroconvulsive therapy in patients with mood disorders

Effect of thiamine on cognitive symptom in the patients with mood disorder in the depression phase under electroconvulsive therapy (clinical trial- double blind)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190525043700N3

Enrollment

Registered

2021-03-12

Start date

2021-03-10

Completion date

Unknown

Last updated

2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive Symptom. Other symptoms and signs involving cognitive functions and awareness

Interventions

Intervention 1: Intervention group: Thiamine (pharmaceutical drug Sanamod) will be started 24 hours before electroconvulsive therapy at a dose of 100 mg daily and this daily dose will continue for up

Eligibility

Sex/Gender

All

Age

20 Years to 50 Years

Inclusion criteria

Inclusion criteria: Patients aged 20-50 years with depressive phase of mood disorders

Exclusion criteria

Exclusion criteria: Patients with a history of alcohol and other substance use in the month before enrollment Epilepsy Mental retardation Cognitive disorders such as delirium and dementia History of thiamine use in the month before enrollment Anemia Malnutrition

Design outcomes

Primary

Measure	Time frame
Cognitive ability. Timepoint: It will be measured 24 hours before and 24 hours after the end of electroconvulsive therapy sessions and also two months after the end of electroconvulsive therapy. Method of measurement: Addenbrooke's Cognitive Examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRomina Hamzehpour

Babol University of Medical Sciences

r.hamzehpour@mubabol.ac.ir+98 11 3233 8301

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026